Ethnic Variations in Antidepressant Response

• Status: Completed
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This 11-week study aims to determine how genetic factors affect the way African Americans and Caucasians with major depression respond to antidepressant medication [citalopram (Celexa®)].

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Mental Health (NIMH)
• Treatments: Antidepressive Agents; Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• DSM-IV criteria for Major Depression

• African-American or Caucasian ethnic background (both parents and 3 out of 4 grandparents)

Exclusion Criteria:

• Schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression, or bipolar disorder

• Current drug abuse or history of drug abuse within the past 6 months

• Unstable medical or neurological conditions that interfere with the treatment of depression

• Allergy to citalopram

• Failure to respond to adequate citalopram drug trial (40 mg for at least 6 weeks)

• Seizure disorder

• Pregnancy

• Psychotropic medications, including antidepressants and neuroleptics

• Suicidal ideation or other safety issues

• Fluoxetine (Prozac) or MAOIs (Nardil, Parnate) in the last 2 months

• Ongoing cognitive behavioral therapy or intensive psychotherapy. General talk therapy is acceptable